Posted by PeterMartin on August 11, 2015, at 11:51:42
Vortioxetine (trade name: Brintellix) has been approved since December 2013 for the treatment of depression in adults, but did not become actually available before May 2015. The German Institute for Quality and Efficiency in Health Care (IQWiG) examined in a dossier assessment whether this drug offers an added benefit over the appropriate comparator therapy. Such an added benefit cannot be derived from the dossier because it contained no data evaluable for the assessment.
More:
http://medicalxpress.com/news/2015-08-vortioxetine-depression-hint-added-benefit.html
poster:PeterMartin
thread:1081276
URL: http://www.dr-bob.org/babble/20150806/msgs/1081276.html